23 of 26 (88%) patients remained free of clinically significant infections caused by any of six…
Categoría: Business Wire
Category Added in a WPeMatico Campaign
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
– The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis)…
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progyny, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES–(BUSINESS WIRE)–$PGNY #PGNY—The Schall Law Firm, a national shareholder rights litigation firm, announces that it…
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
– Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen…
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims on Behalf of Investors in FTX Tokens
LOS ANGELES–(BUSINESS WIRE)–$FTT #FTT—The Schall Law Firm, a national shareholder rights litigation firm, announces that it…
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
Data showed high objective response rate of 61% in RRMM patients with no prior BCMA-targeted treatment,…
Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Significantly Improved Relapse-Free Survival at 64th ASH Annual Meeting
– Updated data from Phase 1b/2 trials include 151 patients with acute myeloid leukemia, acute lymphocytic…
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
Oral presentation at 64th American Society of Hematology Annual Meeting includes promising results from 81 patients…
Hoosier Supports Childhood Cancer Foundation with Silent Auction of Hoosier Hero Card
INDIANAPOLIS–(BUSINESS WIRE)–Hoosier Racing Tire announced its new Hoosier Hero program during this year’s Performance Racing Industry…
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
Findings from clinical studies (N=63) through eight years of long-term follow-up (n=3) continue to support ZYNTEGLO…